Phathom Pharmaceuticals (NASDAQ:PHAT - Get Free Report) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 1st. Analysts expect the company to announce earnings of ($1.06) per share and revenue of $27.91 million for the quarter.
Phathom Pharmaceuticals Stock Down 1.6 %
NASDAQ:PHAT traded down $0.07 during trading hours on Wednesday, reaching $4.29. The company had a trading volume of 1,178,642 shares, compared to its average volume of 1,029,857. The business's 50-day simple moving average is $5.06 and its two-hundred day simple moving average is $7.99. The firm has a market cap of $298.79 million, a price-to-earnings ratio of -0.75 and a beta of 0.35. Phathom Pharmaceuticals has a twelve month low of $3.81 and a twelve month high of $19.71.
Analyst Ratings Changes
PHAT has been the subject of several research reports. Cantor Fitzgerald raised shares of Phathom Pharmaceuticals to a "strong-buy" rating in a research report on Tuesday, February 25th. HC Wainwright reiterated a "buy" rating and set a $28.00 price target on shares of Phathom Pharmaceuticals in a report on Friday, March 7th. Needham & Company LLC reiterated a "buy" rating and issued a $28.00 target price on shares of Phathom Pharmaceuticals in a research note on Monday, April 21st. Craig Hallum reiterated a "buy" rating on shares of Phathom Pharmaceuticals in a research note on Friday, March 7th. Finally, The Goldman Sachs Group cut their price objective on shares of Phathom Pharmaceuticals from $12.00 to $10.00 and set a "neutral" rating for the company in a report on Thursday, April 17th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Phathom Pharmaceuticals presently has an average rating of "Buy" and a consensus price target of $21.83.
Check Out Our Latest Research Report on Phathom Pharmaceuticals
About Phathom Pharmaceuticals
(
Get Free Report)
Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.
See Also
Before you consider Phathom Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phathom Pharmaceuticals wasn't on the list.
While Phathom Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
